Table 2 Patients’ characteristics
High-volume hospital (n = 1842) | Non-high-volume hospital (n = 911) | P value | |
|---|---|---|---|
Age, years (median ± SD) | 69 ± 6.0 | 68 ± 6.1 | 0.001 |
BMI (median ± SD) | 23.6 ± 2.9 | 23.6 ± 3.0 | 0.68 |
Initial PSA ng/mL (median ± SD) | 7.9 ± 7.8 | 7.0 ± 6.0 | < 0.001 |
Clinical T stage (number, %) | |||
T1 | 406 (22.0%) | 137 (15.0%) | < 0.001 |
T2 | 1303 (70.7%) | 696 (76.4%) | |
T3 | 131 (7.1%) | 78 (8.6%) | |
Biopsy Gleason score (number, %) | |||
6 | 403 (21.9%) | 188 (20.6%) | 0.80 |
7 | 958 (52.0%) | 481 (52.8%) | |
8–10 | 480 (26.1%) | 242 (26.6%) | |
D’Amico risk classification (number, %) | |||
Low | 249 (13.5%) | 101 (11.1%) | 0.054 |
Intermediate | 824 (44.7%) | 391 (42.9%) | |
High | 769 (41.7%) | 419 (46.0%) | |
Prostate volume, mL (median ± SD) | 30.2 ± 15.7 | 28.0 ± 17.2 | 0.02 |
Observation period, months (median ± SD) | 30.4 ± 26.7 | 17.6 ± 16.5 | < 0.001 |